FAM110B

Across TCGA pan-cancer cohorts, FAM110B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM110B data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM110B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FAM110B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and HNSC are the cancer types where FAM110B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	1.000	0.458	.021	9	view →
GBM	DFS	Quartile	All	0.529	0.331	.034	6	view →
HNSC	DFS	Median	II,III,IV	1.000	0.536	.049	4	view →
LUAD	DFS	Tertile	III,IV	0.512	1.000	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM110B–CCRCC (DFS)

Open the CCRCC breakdown →